Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...
While autologous hematopoietic stem cell transplantation (aHSCT) has shown promise as a one-time treatment option for relapsing-remitting multiple sclerosis (RRMS), it’s still unclear what role aHSCT ...
Five separate mediation analyses found that adaptive coping had a significant association with each PWB subscale and self-efficacy. After controlling for self-efficacy, there remained separate ...
Everyday Health on MSN
Understanding the Shift from Relapsing-Remitting MS to Secondary-Progressive MS
Be ready for the possible transition from RRMS to SPMS by understanding new symptoms, treatment options, and what to discuss ...
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, ...
Women with multiple sclerosis, particularly after menopause, experience a higher risk of relapse-independent worsening, ...
A prospective study found evidence of serum neurofilament light (sNfL) level increases in patients affected by active forms of relapsing-remitting multiple sclerosis (RRMS); however, these findings ...
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable ...
Please provide your email address to receive an email when new articles are posted on . Study examined 41 individuals with RRMS and 20 healthy controls required to wear accelerometer for 1 week.
Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results